Pediatric Nephrology

, Volume 23, Issue 9, pp 1391–1394 | Cite as

Therapies for steroid-resistant nephrotic syndrome

Editorial Commentary

Abstract

Between 10 and 20% of children with primary nephrotic syndrome are steroid-resistant (SRNS). From earlier studies in children with SRNS, we know that cyclosporin (with or without alternate-day prednisone) and cyclophosphamide (with pulse intravenous corticosteroids) result in comparable complete or partial remission rates of about 60%. An evaluation of the relative effectiveness of cyclophosphamide and cyclosporin has not been possible because of the absence of a head-to-head randomised trial. The Arbeitsgemeinschaft für Pädiatrische Nephrologie trial, published in this issue of Pediatric Nephrology, has filled this gap in our evidence base. Although there was no difference in the number of patients achieving complete remission, those patients receiving cyclosporin treatment were significantly more likely to achieve partial remission than those receiving intravenous cyclophosphamide. This result suggests that cyclosporin rather than cyclophosphamide should be used as first line therapy for children with SRNS.

Keywords

Cyclophosphamide Cyclosporin Focal and segmental glomerulosclerosis Minimal change disease Randomised controlled trials 

References

  1. 1.
    McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM (2001) Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 16:1040–1044PubMedCrossRefGoogle Scholar
  2. 2.
    Wong W (2007) Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. J Paediatr Child Health 43:337–341PubMedCrossRefGoogle Scholar
  3. 3.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMedGoogle Scholar
  4. 4.
    Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM (2005) High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 68:1275–1281PubMedCrossRefGoogle Scholar
  5. 5.
    International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561–564CrossRefGoogle Scholar
  6. 6.
    Borges FF, Shiraichi L, da Silva MP, Nishimoto EI, Nogueira PC (2007) Is focal segmental glomerulosclerosis increasing in patients with nephrotic syndrome? Pediatr Nephrol 22:1309–1313PubMedCrossRefGoogle Scholar
  7. 7.
    Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewiski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722–732PubMedCrossRefGoogle Scholar
  8. 8.
    Weber S, Gribouval O, Esquivel EL, Morinière V, Tête MJ, Legendre C, Niaudet P, Antignac C (2004) NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 66:571–579PubMedCrossRefGoogle Scholar
  9. 9.
    Berdeli A, Mir S, Yavascan O, Serdaroglu E, Bak M, Aksu N, Oner A, Anarat A, Donmez O, Yildiz N, Sever L, Tabel Y, Dusunsel R, Sonmez F, Cakar N (2007) NPHS2 (podicin) mutations in Turkish children with idiopathic nephrotic syndrome. Pediatr Nephrol 22:2031–2040PubMedCrossRefGoogle Scholar
  10. 10.
    Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183–2193PubMedCrossRefGoogle Scholar
  11. 11.
    Schwaderer P, Knuppel T, Konrad M, Mehls O, Scharer K, Schaefer F, Weber S (2008) Clinical course and NPHS2 analysis in patients with late steroid-resistant nephrotic syndrome. Pediatr Nephrol 23:251–256PubMedCrossRefGoogle Scholar
  12. 12.
    Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ (2006) Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 21:967–972PubMedCrossRefGoogle Scholar
  13. 13.
    Bagga A, Mudigoudar BD, Hari P, Vasudev V (2004) Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 19:45–50PubMedCrossRefGoogle Scholar
  14. 14.
    Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72–79PubMedCrossRefGoogle Scholar
  15. 15.
    Abrantes MM, Cardosa LSB, Lima EM, Silva JMP, Diniz JS, Bambirra EA, Oliveira EA (2006) Clinical course of 110 children and adolescents with primary focal segmental glomerulosclerosis. Pediatr Nephrol 21:482–489PubMedCrossRefGoogle Scholar
  16. 16.
    Abeyagunawardena AS, Sebire NJ, Risdon RA, Dillon MJ, Rees L, van’t Hoff W, Kumarasiri PV, Trompeter RS (2007) Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 22:215–221PubMedCrossRefGoogle Scholar
  17. 17.
    Hari P, Bagga A, Jindal N, Srivastava RN (2001) Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 16:901–905PubMedCrossRefGoogle Scholar
  18. 18.
    Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN (2003) Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol 18:351–356PubMedGoogle Scholar
  19. 19.
    Hari P, Bagga A, Mantan M (2004) Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 41:993–1000PubMedGoogle Scholar
  20. 20.
    Niaudet P (1994) Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 125:981–986PubMedCrossRefGoogle Scholar
  21. 21.
    Pena A, Bravo J, Melgosa M, Fernandez C, Meseguer C, Espinosa L, Alonso A, Picazo ML, Navarro M (2007) Steroid-resistant nephrotic syndrome: long-term evaluation after sequential therapy. Pediatr Nephrol 22:1875–1880PubMedCrossRefGoogle Scholar
  22. 22.
    International Study of Kidney Disease in Children (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20:765–771CrossRefGoogle Scholar
  23. 23.
    Hodson EM, Habashy D, Craig JC (2006) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev (2):CD003594Google Scholar
  24. 24.
    Singh A, Tejani C, Tejani A (1999) One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 13:26–32PubMedCrossRefGoogle Scholar
  25. 25.
    Durkan A, Hodson EM, Willis NS, Craig JC (2005) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev (2):CD002290Google Scholar
  26. 26.
    Kleinknecht C, Broyer M, Gubler MC, Palcoux JB (1980) Irreversible renal failure after indomethacin in steroid resistant nephrosis. N Engl J Med 302:961Google Scholar
  27. 27.
    International study of Kidney Disease in Children (1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 2:423–427Google Scholar
  28. 28.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1996) Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 10:590–593PubMedCrossRefGoogle Scholar
  29. 29.
    Martinelli R, Pereira LJ, Silva OM, Okumura AS, Rocha H (2004) Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Braz J Med Biol Res 37:1365–1372PubMedCrossRefGoogle Scholar
  30. 30.
    Elhence R, Gulati S, Kher V, Gupta A, Sharma RK (1994) Intravenous pulse cyclophosphamide—a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol 8:1–3PubMedCrossRefGoogle Scholar
  31. 31.
    Gulati S, Kher V (2000) Intravenous pulse cyclophosphamide—a new regime for steroid-resistant focal segmental glomerulosclerosis. Indian Pediatr 37:141–148PubMedGoogle Scholar
  32. 32.
    Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88PubMedGoogle Scholar
  33. 33.
    Mantan M, Bagga A, Sriram CS, Hari P (2004) Efficacy of pulse cyclophosphamide (CP) vs IV steroids and oral CP for steroid resistant nephrotic syndrome. Pediatr Nephrol 19:C73Google Scholar
  34. 34.
    Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W; Arbeitsgemeinschaft für Pädiatrische Nephrologie (2008) Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol DOI  10.1007/s00467-008-0794-1
  35. 35.
    Cattran DC, Wang MM, Appel G, Matalon A, Briggs W (2004) Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 62:405–411PubMedGoogle Scholar
  36. 36.
    Bhimma R, Adhikari M, Asharam K, Connolly C (2006) Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 26:544–551PubMedCrossRefGoogle Scholar
  37. 37.
    Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751–2752PubMedCrossRefGoogle Scholar
  38. 38.
    Trachtman H, Gipson DS, Vento S, Thomson PD, Dike M (2007) Novel therapies for resistant FSGS: Preliminary results. Pediatr Nephrol 22:1629CrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  1. 1.Centre for Kidney ResearchThe Children’s Hospital at WestmeadWestmeadAustralia
  2. 2.School of Public HealthUniversity of SydneySydneyAustralia

Personalised recommendations